# A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

> **NCT06683885** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mingzhi Zhang** · enrollment: 80 (estimated)

## Conditions studied

- Newly Diagnosed Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone

## Key facts

- **NCT ID:** NCT06683885
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683885, "A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06683885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*